Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc. develops cell-based technologies built around its proprietary 3D cell expansion platform. Company news commonly covers mass-scale cell expansion, biofarming, regenerative medicine applications, immune-cell manufacturing intellectual property, and the use of PluriCDMO™ for contract development and manufacturing programs involving cell-derived therapeutics, biologics, and placenta-derived biomaterials.
Recurring updates also address Pluri’s venture and subsidiary activity across foodtech, agtech, and health and aesthetics, including Coffeesai, Ever After Foods, Kokomodo, and Cellav. Additional news themes include commercial collaborations, patent grants, board and governance changes, private placements, and other capital actions tied to Pluri’s platform, subsidiaries, and public-company structure.
Pluri Inc. (Nasdaq: PLUR) announced its participation in three key conferences: CPHI Frankfurt from November 1-3, 2022, Jefferies London Healthcare Conference from November 15-17, 2022, and a virtual conference on Mesenchymal Stem Cells from November 17-19, 2022. Key executives including the Chief Commercial Officer and Chief Medical Officer will represent Pluri. These events aim to foster networking and knowledge sharing within the pharmaceutical and biotechnology sectors.
Pluri focuses on innovative cell-based solutions, advancing regenerative medicine, food technology, and biologics.
Pluri Inc. (Nasdaq: PLUR) has announced a new strategy that will reduce its annual cash burn by 30%, aiming to lower it from $36 million to approximately $24 million. The company currently has $56 million in cash reserves as of June 30, 2022. Pluri has entered a collaboration agreement with a leading European manufacturer to develop biologic APIs using its 3D cell expansion technology, which aims to provide cost-effective and cruelty-free solutions. This partnership marks Pluri's second technology collaboration, following its agreement with Tnuva Group for cultivated food products.
Pluri Inc. (Nasdaq: PLUR) has secured a €7.5 million non-dilutive grant from the European Union’s Horizon Europe program for the PROTO project, focused on treating knee osteoarthritis (OA) using PLX-PAD cells. The Phase I/IIa clinical study will be led by Charité, with Professor Tobias Winkler directing the project. The grant's final approval is pending consortium agreements. The initiative aims to address the substantial healthcare burden of OA, which affects over 500 million people globally. PLX-PAD represents a promising treatment avenue, aiming to modify disease progression.
Pluri Inc. (Nasdaq: PLUR) has announced its new corporate name, reflecting a strategic evolution aimed at creating innovative cell-based products for diverse industries. CEO Yaky Yanay highlighted the Phoenix Project, initiated in early 2021, to strengthen the company’s foundation through advanced cell technology and partnerships. Pluri targets collaborations in sectors like food-tech and pharma, focusing on regenerative medicine and gene-edited cell therapies. The company aims to drive medical research while addressing global challenges such as sustainability.
Pluri Inc. (Nasdaq: PLUR), formerly known as Pluristem Therapeutics, announced its name change effective July 26, 2022, indicating a shift in strategy. The company aims to leverage its innovative 3D cell-based technology across various sectors, including food-tech and agri-tech. CEO Yaky Yanay highlighted the demand for scalable and efficient cell-based solutions. Pluri's technology remains dedicated to advancing medical research while also addressing global challenges such as food scarcity and sustainability. The new identity underscores its commitment to broader applications of biotechnological solutions.